Recap: Quidel Q3 Earnings

Shares of Quidel QDEL fell 1.5% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 725.71% over the past year to $5.78, which beat the estimate of $4.75.

Revenue of $476,058,000 up by 276.35% year over year, which beat the estimate of $450,390,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Quidel hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Oct 29, 2020

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/wcc/r/2625296/E75E2243C47118925001E5956E2A2D04

Technicals

52-week high: $306.72

52-week low: $55.42

Price action over last quarter: down 6.89%

Company Description

Quidel Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. It is separated into four product categories: Rapid immunoassays, Cardiac immunoassays, Specialized diagnostic solutions and Molecular diagnostic solutions. Rapid immunoassay and Cardiac immunoassay tests for use in physician offices, hospital laboratories and emergency departments, retail clinics, eye health settings, pharmacies and other urgent care sites, Specialized diagnostic solutions, including direct fluorescent assays and culture-based tests, and Molecular diagnostic tests across a number of hospitals, moderately complex physician offices, laboratories and other segments. The company generates a majority of its revenue from the rapid immunoassays.